Immatics N.V.IMTX

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$8.33
Market cap
$1.1B
P/E
—
Revenue (FY)
—
Net income
-$196.4M
Dividend yield
—
1-year total return
18.2%
Net margin
—
Revenue growth
—
Debt / equity
—

What Immatics N.V. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Net income-$211.3M-$93.3M$27.7M-$94.6M$15.2M-$196.4M
Free cash flow-$88.1M-$89.9M$94.4M-$12.6M-$174.3M-$183.2M

More on IMTX.

Figures from Immatics N.V.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.